38 commercial payer policies list J0222. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
38 policies from 19 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J0222 |
|---|---|---|
| Onpattro (patisiran) | Aug 1, 2025 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Onpattro (patisiran) | Not recorded | Prior auth requiredInferred from policy title |
| Onpattro (patisiran) | Oct 1, 2024 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Onpattro (Patisiran) | Feb 1, 2023 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Onpattro (Patisiran) | Sep 1, 2023 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Patisiran (Onpattro) | Jul 1, 2020 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Patisiran (Onpattro) | Nov 1, 2022 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Patisiran (Onpattro) | Dec 1, 2018 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Patisiran (Onpattro) | Aug 1, 2019 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Patisiran (Onpattro) | Jul 1, 2021 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Policy | Effective | Status of J0222 |
|---|---|---|
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| RNA-Targeted Therapies (Amvuttra and Onpattro) | Jun 1, 2026 | Covered |
| RNA-Targeted Therapies (Amvuttra and Onpattro) – Commercial and Individual Exchange Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| RNA-Targeted Therapies (Amvuttra and Onpattro) – Community Plan Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| patisiran (Onpattro) and vutrisiran (Amvuttra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Patisiran (Onpattro) and vutrisiran (Amvuttra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Vutrisiran (Amvuttra) and Patisiran (Onpattro) | Jan 1, 2026 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Vutrisiran (Amvuttra) and Patisiran (Onpattro) | Jan 1, 2026 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Vutrisiran (Amvuttra) and Patisiran (Onpattro) | Jan 1, 2026 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Vutrisiran (Amvuttra) and Patisiran (Onpattro) | Jan 1, 2026 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| patisiran (Onpattro) and vutrisiran (Amvuttra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Patisiran (Onpattro) and vutrisiran (Amvuttra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| RNA-Targeted Therapies (Amvuttra and Onpattro) | Jun 1, 2026 | Covered |
| Policy | Effective | Status of J0222 |
|---|---|---|
| Treatment of Hereditary Transthyretin-mediated Amyloidosis [Patisiran (e.g., Onpattro) and Vutrisiran (e.g., Amvuttra)] | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| Vutrisiran (Amvuttra) and Patisiran (Onpattro) | Jan 1, 2026 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| ONPATTRO (PATISIRAN) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| Patisiran Lipid Complex (Onpattro) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| Pharmacologic Treatment of Hereditary Transthyretin-Mediated Amyloidosis (Onpattro/Tegsedi/Amvuttra) | Aug 1, 2019 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| hATTR medications - patisiran (Onpattro) and vutrisiran (Amvuttra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| Onpattro,Tegsedi and Amvuttra | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| Patisiran (Onpattro) | Sep 11, 2020 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| Onpattro (patisiran lipid complex) Listed in Moda Health's provider indexes for Oregon, Alaska, Idaho, Texas. The document does not establish the member's state or line of business. | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0222 |
|---|---|---|
| RNA-Targeted Therapies (Amvuttra and Onpattro) | Jun 1, 2026 | Covered |